[go: up one dir, main page]

WO2005010153A3 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof Download PDF

Info

Publication number
WO2005010153A3
WO2005010153A3 PCT/US2004/021002 US2004021002W WO2005010153A3 WO 2005010153 A3 WO2005010153 A3 WO 2005010153A3 US 2004021002 W US2004021002 W US 2004021002W WO 2005010153 A3 WO2005010153 A3 WO 2005010153A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastasis
library
present
fragments
compositions
Prior art date
Application number
PCT/US2004/021002
Other languages
French (fr)
Other versions
WO2005010153A2 (en
Inventor
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yael Nisgav
Tali Szrajber
Yariv Kanfi
Original Assignee
Bio Technology General Israel
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yael Nisgav
Tali Szrajber
Yariv Kanfi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Israel, Daniel Plaksin, Avigdor Levanon, Esther Szanton, Yocheved Hagay, Rachel Ben-Levy, Yael Nisgav, Tali Szrajber, Yariv Kanfi filed Critical Bio Technology General Israel
Priority to CA002536644A priority Critical patent/CA2536644A1/en
Priority to BRPI0411945-2A priority patent/BRPI0411945A/en
Priority to MXPA06000252A priority patent/MXPA06000252A/en
Priority to JP2006518730A priority patent/JP2007528711A/en
Priority to EP04777308A priority patent/EP1649001A2/en
Priority to AU2004259406A priority patent/AU2004259406A1/en
Publication of WO2005010153A2 publication Critical patent/WO2005010153A2/en
Priority to IL172510A priority patent/IL172510A0/en
Publication of WO2005010153A3 publication Critical patent/WO2005010153A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using such antibody fragments thereof are also provided. The methods and compositions according to the present invention can be used in targeting therapeutic agents and in diagnosis, prognosis, and staging of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease. Also provided is a library of immunoglobulin binding domains having a diverse antigen-binding domain for complementary binding, wherein the library has diversity only in heavy chain CDR3.
PCT/US2004/021002 2003-06-30 2004-06-30 Antibodies and uses thereof WO2005010153A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002536644A CA2536644A1 (en) 2003-06-30 2004-06-30 Antibodies and uses thereof
BRPI0411945-2A BRPI0411945A (en) 2003-06-30 2004-06-30 Antibodies and their uses
MXPA06000252A MXPA06000252A (en) 2003-06-30 2004-06-30 Antibodies and uses thereof.
JP2006518730A JP2007528711A (en) 2003-06-30 2004-06-30 Antibodies and uses thereof
EP04777308A EP1649001A2 (en) 2003-06-30 2004-06-30 Antibodies and uses thereof
AU2004259406A AU2004259406A1 (en) 2003-06-30 2004-06-30 Antibodies and uses thereof
IL172510A IL172510A0 (en) 2003-06-30 2005-12-12 Antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61123803A 2003-06-30 2003-06-30
US10/611,238 2003-06-30

Publications (2)

Publication Number Publication Date
WO2005010153A2 WO2005010153A2 (en) 2005-02-03
WO2005010153A3 true WO2005010153A3 (en) 2008-03-13

Family

ID=34103137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021002 WO2005010153A2 (en) 2003-06-30 2004-06-30 Antibodies and uses thereof

Country Status (11)

Country Link
EP (1) EP1649001A2 (en)
JP (1) JP2007528711A (en)
KR (1) KR20060106631A (en)
CN (1) CN101300021A (en)
AU (1) AU2004259406A1 (en)
BR (1) BRPI0411945A (en)
CA (1) CA2536644A1 (en)
IL (1) IL172510A0 (en)
MX (1) MXPA06000252A (en)
RU (1) RU2006102570A (en)
WO (1) WO2005010153A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714978A1 (en) * 2005-04-19 2006-10-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides useful for diagnosis and therapy of tumors
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
EP2161072A1 (en) * 2008-09-03 2010-03-10 Gambro Lundia AB High cut-off hemodialysis membranes for the treatment of chronic hemodialysis patients
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
SI2804878T1 (en) * 2012-01-20 2018-12-31 Genzyme Corporation Anti-cxcr3 antibodies
CN106659784B (en) 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 PSGL-1 modulators and uses thereof
RU2766000C2 (en) 2016-01-08 2022-02-07 АльтруБио Инк. Tetravalent antibodies to psgl-1 and their applications
CN115989412A (en) * 2020-04-27 2023-04-18 西西欧艾(杭州)生物医药有限责任公司 Rapid and simple antibody detection using covalently immobilized self-assembled polypeptides
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026667A1 (en) * 1998-10-30 2000-05-11 Miller Jonathan L Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
WO2002053700A2 (en) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026667A1 (en) * 1998-10-30 2000-05-11 Miller Jonathan L Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
WO2002053700A2 (en) * 2000-12-29 2002-07-11 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WARD ET AL.: "Mocarhagin, a Novel Cobra Venom Metalloproteinase, Cleaves the Platelet von Willebrand Factor Receptor Glycoprotein Iba. Identification of the Sulfated Tyrosine/Anionic Sequence Tyr-276-Glu-282 of Glycoprotein Iba as a Binding Site for von Willebrand.....", BIOCHEMISTRY, vol. 35, no. 15, 1996, pages 4929 - 4938 *

Also Published As

Publication number Publication date
EP1649001A2 (en) 2006-04-26
IL172510A0 (en) 2006-04-10
KR20060106631A (en) 2006-10-12
AU2004259406A1 (en) 2005-02-03
MXPA06000252A (en) 2006-12-15
BRPI0411945A (en) 2006-10-24
CN101300021A (en) 2008-11-05
RU2006102570A (en) 2007-08-20
CA2536644A1 (en) 2005-02-03
WO2005010153A2 (en) 2005-02-03
JP2007528711A (en) 2007-10-18

Similar Documents

Publication Publication Date Title
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
UA90082C2 (en) SEPARATE MONOCLONAL ANTIBODY OF HUMANS SPECIFICALLY Binding TO CD25 HUMANS AND INHIBITING IL-2 Binding TO CD25
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
JP2018538262A5 (en)
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
IL242336A (en) Method of detecting ca6 glycotope and use of a cytotoxic conjugate in the preparation of a medicament for treating cancer in a subject diagnosed with said cancer in accordance with said method
WO2007073499A3 (en) Epha2 bite molecules and uses thereof
WO2008047242A3 (en) Novel anti-cd38 antibodies for the treatment of cancer
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2010017500A3 (en) Anti-pancreatic cancer antibodies
EP2269656A3 (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
EP3530736A3 (en) Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
WO2009067660A3 (en) Anti-factor xi monoclonal antibodies and methods of use thereof
WO2005058815A3 (en) Ip-10 antibodies and their uses
WO2007016590A3 (en) Ovr232v3 antibody compositions and methods of use
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
WO2004101756A3 (en) Ovr110 antibody compositions and methods of use
WO2006116451A3 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells
GEP20135826B (en) Novel antibodies used to treat cancer
WO2005010153A3 (en) Antibodies and uses thereof
TW200517124A (en) Fully human antibodies against human 4-1BB
MX2007004247A (en) Angiopoietin-2 specific binding agents.
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024914.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172510

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020057025517

Country of ref document: KR

Ref document number: 2536644

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006518730

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000252

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 545005

Country of ref document: NZ

Ref document number: 2006102570

Country of ref document: RU

Ref document number: 200600862

Country of ref document: ZA

Ref document number: 2004777308

Country of ref document: EP

Ref document number: 2004259406

Country of ref document: AU

Ref document number: 485/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004259406

Country of ref document: AU

Date of ref document: 20040630

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004777308

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 1020057025517

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0411945

Country of ref document: BR